NASDAQ : SLN
Silence Therapeutics plc — Key statistics
Healthcare · Biotechnology · United Kingdom
Last price 19.75 USD (Oct 30, 2026, 3:17 PM EDT) · Market cap 1.19B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.19B |
| Enterprise Value | 1.12B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 60.21M |
| Shares Change (YoY) | +0.09% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 14.84% |
| Owned by Institutions (%) | 38.36% |
| Float | 48.24M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,937.47 |
| Forward PS | 2,276.36 |
| PB Ratio | 24.26 |
| P/TBV Ratio | 42.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1,820.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.42 |
| Quick Ratio | 6.40 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -90.41% |
| Return on Assets (ROA) | -29.65% |
| Return on Invested Capital (ROIC) | -60.67% |
| Return on Capital Employed (ROCE) | -68.76% |
| Weighted Average Cost of Capital (WACC) | 12.20% |
| Revenue Per Employee | $6,989 |
| Profits Per Employee | -$681,284 |
| Employee Count | 88 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 2,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.45 |
| 52-Week Price Change | +176.26% |
| 50-Day Moving Average | 13.61 |
| 200-Day Moving Average | 9.13 |
| Relative Strength Index (RSI) | 78.98 |
| Average Volume (20 Days) | 5,894,230 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.93M |
| Short Previous Month | 2.54M |
| Short % of Shares Out | 5.78% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.70 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 615,000 |
| Gross Profit | 528,000 |
| Operating Income | -64.43M |
| Pretax Income | -59.95M |
| Net Income | -59.95M |
| EBITDA | -63.94M |
| EBIT | -64.43M |
| Loss Per Share | -$3.81 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 72.05M |
| Total Debt | 112,000 |
| Net Cash | 71.94M |
| Net Cash Per Share | $1.19 |
| Equity (Book Value) | 38.47M |
| Book Value Per Share | 0.81 |
| Working Capital | 81.57M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -42.26M |
| Capital Expenditures | -3,000 |
| Depreciation & Amortization | 483,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -42.27M |
| FCF Per Share | -$0.70 |
Margins
| Measure | Value |
|---|
| Gross Margin | 85.85% |
| Operating Margin | -10,475.61% |
| Pretax Margin | -9,748.13% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.09% |
| Shareholder Yield | -0.09% |
| Earnings Yield | -19.26% |
| FCF Yield | -3.55% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $19.75 |
| Price Target Difference | -0.13% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -25.48% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -6.32 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |